Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.36 |
| ▸ | PTGIR | P43119 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493441 | 0.94 | AVPR1A (0.40) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493788 | 0.94 | AVPR1B (0.37) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493722 | 0.94 | AVPR1B (0.37) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL492717 | 0.92 | BDKRB1 (0.33) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL492554 | 0.92 | CXCR3 (0.40) | ALDH1A1LMNASMN1; SMN2CXCR3PTGIR | |
| SCHEMBL493437 | 0.91 | AVPR1A (0.38) | AVPR1AAVPR1BALDH1A1LMNAF2 | |
| SCHEMBL492956 | 0.90 | BDKRB1 (0.38) | AVPR1BPTGIR | |
| SCHEMBL493275 | 0.90 | AVPR1A (0.40) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL493601 | 0.87 | AVPR1B (0.37) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL494497 | 0.87 | AVPR1B (0.38) | AVPR1AAVPR1BALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | AVPR1A 537/4885AVPR1B 780/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.